Insulin receptor partial agonists and GLP-1 analogues
View Patent ↗The present invention provides compositions comprising insulin receptor partial agonists in association with GLP-1 analogues (e.g., liraglutide) as well as methods for using the compositions for example, to treat or prevent diabetes or to decrease body weight.
1. A composition comprising an insulin receptor partial agonist or insulin dimer, wherein the insulin receptor partial agonist or insulin dimer is:
in association with a GLP-1 analogue, with the proviso that the GLP-1 analogue is not exenatide.
2. The composition of claim 1 , wherein the GLP-1 analogue is liraglutide
albiglutide, dulaglutide or taspoglutide.
3. A pharmaceutical composition comprising the composition of claim 1 and a pharmaceutically acceptable carrier.
4. The composition of claim 1 wherein said insulin receptor partial agonist or insulin dimer and said GLP-1 analogue are in separate containers.
5. The composition of claim 1 in association with a further therapeutic agent.
6. The composition of claim 5 wherein the further therapeutic agent is one or more members selected from group consisting of: acarbose; alogliptin; alpha-glucosidase inhibitors;
amylinomimetic; biguanide; bromocriptine; canagliflozin; chlorpropamide; dapagliflozin; dopamine agonist;
empagliflozin; gliclazide; glimepiride; glipizide; glyburide; insulin, linagliptin; meglitinide; metformin;
miglitol; nateglinide; pioglitazone; pramlintide; repaglinide; rosiglitazone; saxagliptin; sitagliptin; sulfonylurea;
thiazolidinedione; tolazamide; tolbutamide; atorvastatin; cerivastatin; fluvastatin; lovastatin; mevastatin;
pitavastatin; pravastatin; rosuvastatin; simvastatin; simvastatin and ezetimibe; lovastatin and niacin; atorvastatin and amlodipine besylate; simvastatin and niacin; and ezetimibe.
7. A method for treating diabetes or for causing body weight reduction in a subject comprising administering a composition of claim 1 to the subject.